Laird Norton Wetherby Wealth Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$577K	Buy	1,266 +40	+3%	+$16.3K	0.02%	527
2025 Q2	$400K	Buy	+1,226	New	+$339K	0.02%	641
2024 Q4	$270K	Sell	1,147 -204	-15%	-$53.7K	0.01%	731
2024 Q3	$372K	Buy	1,351 +202	+18%	+$52.6K	0.02%	658
2024 Q2	$279K	Sell	1,149 -297	-21%	-$46.9K	0.01%	738
2024 Q1	$216K	Sell	1,446 -177	-11%	-$29.5K	0.01%	860
2023 Q4	$311K	Buy	1,623 +326	+25%	+$55.5K	0.02%	711
2023 Q3	$230K	Sell	1,297 -256	-16%	-$48.8K	0.01%	774
2023 Q2	$295K	Buy	1,553 +191	+14%	+$37.9K	0.02%	722
2023 Q1	$273K	Sell	1,362 -123	-8%	-$25.9K	0.02%	739
2022 Q4	$353K	Sell	1,485 -202	-12%	-$43.1K	0.02%	633
2022 Q3	$338K	Buy	+1,687	New	+$322K	0.02%	616
2022 Q2	–	Sell	-1,313	Closed	-$214K	–	908
2022 Q1	$214K	Buy	1,313 +3	+0.2%	+$457	0.01%	839
2021 Q4	$222K	Buy	1,310 +48	+4%	+$8.92K	0.01%	822
2021 Q3	$238K	Buy	1,262 +51	+4%	+$9.57K	0.01%	796
2021 Q2	$205K	Buy	+1,211	New	+$177K	0.01%	863